Biomarker Analysis Services

Biomarkers serve as measurable biological indicators that bridge molecular changes to phenotypic outcomes, enabling researchers to decode drug mechanisms, monitor therapeutic responses, and stratify model populations with unprecedented precision in preclinical settings. At Alfa Cytolog, we translate complex biological signals into actionable preclinical data through our integrated biomarker analysis platform, empowering your oncology programs from target validation through IND-enabling studies.

Overview of Biomarker Analysis

In contemporary oncology research, biomarkers have evolved from simple diagnostic indicators into multidimensional tools that inform every stage of preclinical therapeutic development. These molecular signatures—encompassing genomic alterations, protein expression patterns, metabolite profiles, and immune cell dynamics—provide critical insights into tumor heterogeneity, treatment resistance, and model-specific response trajectories. The integration of multi-omics approaches has dramatically expanded the biomarker landscape, allowing researchers to correlate genetic mutations with phenotypic outcomes and to identify predictive signatures that guide compound prioritization and responder stratification strategies in animal models.

Fig 1. Research ecosystem foundation of biomarker research. (Bujang, Mohamad Adam, et al., 2026)

The tumor microenvironment (TME) represents a particularly rich source of biomarker discovery, where spatial relationships between malignant cells, immune infiltrates, stromal components, and extracellular matrix elements collectively determine therapeutic efficacy. Advanced analytical platforms now enable simultaneous detection of dozens of protein markers within intact tissue architecture, preserving the contextual information that conventional dissociation-based methods often lose. This spatial dimension has proven essential for distinguishing immune-excluded from immune-ignorant tumor phenotypes in preclinical models and for identifying predictive signatures—such as intratumoral-to-peritumoral T-cell density ratios—that outperform single-marker assessments in forecasting treatment outcomes in in vivo settings.

Multiplex Technologies Reshaping Immuno-Oncology Biomarker Discovery

Our Services

Alfa Cytolog delivers end-to-end preclinical biomarker analysis services designed to de-risk your oncology pipeline and accelerate translational decision-making. Our integrated platform spans in vivo pharmacology studies, ex vivo tissue characterization, and in vitro mechanism-of-action assays—ensuring seamless continuity from preclinical model selection through IND-enabling biomarker validation. Whether you require immune phenotyping in syngeneic mouse models, spatial biomarker mapping in patient-derived xenografts (PDX), or serum cytokine monitoring across dosing cohorts, our scientific team tailors each analytical workflow to your compound's unique biology and development stage. We combine state-of-the-art instrumentation with rigorous quality standards to generate robust datasets that support internal decision-making and external stakeholder communication during the preclinical phase.

Our Biomarker Analysis Services

Immune Cell Phenotyping & Flow Cytometry

• Multi-parameter flow cytometry panels for mouse, rat, and NHP preclinical samples
• Immunophenotyping of tumor-infiltrating lymphocytes (TILs), myeloid-derived suppressor cells, and regulatory T cells in in vivo models
• Functional assays including intracellular cytokine staining, proliferation markers, and apoptosis detection
• Custom panel design and antibody validation for novel targets in preclinical species

Histopathology & Multiplex IHC/IF

• Single and multiplex immunohistochemistry (IHC) and immunofluorescence (IF) on FFPE and frozen tissue sections from preclinical models
• Spatial biomarker analysis for tumor microenvironment characterization in in vivo studies
• AI-assisted digital pathology and quantitative image analysis
• Tertiary lymphoid structure (TLS) detection and immune cell density scoring in animal tumor specimens

Genomic & Transcriptomic Profiling

• RNA sequencing (RNA-seq) and whole-exome sequencing (WES) for responder vs. non-responder stratification in preclinical models
• Targeted gene expression panels and qPCR validation for pharmacodynamic assessment
• Single-cell RNA sequencing (scRNA-seq) for rare population identification in tumor samples
• Bioinformatics support including pathway enrichment and variant annotation for preclinical datasets

Serum & Tissue Proteomics

• Meso Scale Discovery (MSD) and ELISA-based cytokine/chemokine profiling from preclinical serum and plasma
• Multiplexed proteomics for pharmacodynamic monitoring across dosing cohorts
• Targeted mass spectrometry for therapeutic protein and ADC linker stability assessment in in vitro and in vivo samples
• Olink proximity extension assays for high-plex protein quantification in preclinical specimens

Radiopharmaceutical Biomarker Support

• Biodistribution and tumor uptake analysis using preclinical imaging platforms
• Biomarker-guided patient-derived model selection for radioligand therapy programs
• Theranostic pairing strategies correlating diagnostic imaging biomarkers with therapeutic response in in vivo models
• FAP, PSMA, and SSTR expression profiling to inform target validation in preclinical tumor models

Bioinformatics & Data Integration

• Integration of multi-omics datasets (genomics, proteomics, imaging) into unified biomarker signatures for preclinical programs
• Machine learning-driven predictive biomarker discovery using preclinical model data
• Correlation of preclinical biomarker data with published human tumor atlases for translational relevance
• Custom reporting with publication-quality figures and statistical analysis for IND-enabling packages

Workflow of Biomarker Analysis

Our biomarker analysis workflow is designed to maximize translational relevance while minimizing experimental variability. Each project begins with a thorough scientific consultation to align analytical endpoints with your therapeutic hypothesis, followed by meticulous sample processing, multi-platform analysis, and integrated data interpretation. The entire process is managed by Ph.D.-level scientists who ensure that every dataset is robust, reproducible, and ready for downstream preclinical decision-making and IND-enabling documentation.

1. Project Consultation & Assay Design: Our scientific team collaborates with you to define biomarker objectives, select appropriate analytical platforms, and design custom panels tailored to your compound's mechanism of action and target indication for preclinical evaluation.

2. Sample Collection & Processing: We establish standardized collection protocols for blood, tissue, and fluid samples from in vivo studies, ensuring optimal preservation of cellular and molecular integrity for downstream preclinical analysis.

3. Multi-Platform Biomarker Analysis: Samples are processed through the selected analytical pipelines—ranging from flow cytometry and multiplex IHC to NGS and proteomics—using validated protocols and instrument-specific quality controls suitable for IND-enabling studies.

4. Data Integration & Bioinformatics: Raw data undergoes rigorous quality control, normalization, and statistical analysis. Multi-omics datasets are integrated using bioinformatics pipelines to identify composite biomarker signatures and correlate findings with treatment outcomes in preclinical models.

5. Interpretation & Reporting: We deliver comprehensive reports featuring publication-ready figures, detailed methodology documentation, and actionable recommendations for compound optimization, responder stratification in animal models, or preclinical biomarker strategy refinement.

Why Choose Alfa Cytolog?

Contact Us

Ready to unlock the full potential of biomarker-driven preclinical drug development? Reach out to us today to discuss how Alfa Cytolog's biomarker analysis services can accelerate your oncology program from target validation through IND-enabling studies. Our scientific team is eager to collaborate on your next project—whether you need a custom multiplex IHC panel, comprehensive immune profiling, or integrated multi-omics data interpretation for your preclinical pipeline. Contact us now and let's build the biomarker strategy that transforms your preclinical data into a compelling development package.

For research use only. Not intended for any clinical use.